ORIGINAL RESEARCH article

Front. Pharmacol., 31 October 2022

Sec. Drugs Outcomes Research and Policies

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.998239

Clinical features, diagnosis and management of amoxicillin-induced Kounis syndrome

  • 1. Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

  • 2. Department of Pharmacy, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan, China

  • 3. Department of Endocrinology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Article metrics

View details

5

Citations

5,7k

Views

1,9k

Downloads

Abstract

Background: The available evidence suggests that amoxicillin is often associated with the occurrence of Kounis syndrome (KS). The purpose of this study is to explore the clinical characteristics of KS induced by amoxicillin.

Methods: We searched for case reports of amoxicillin-induced KS through Chinese and English databases from 1972 to May 2022.

Results: A total of 33 patients with KS were included, including 16 patients (48.5%) receiving amoxicillin treatment and 17 patients (51.5%) receiving amoxicillin-clavulanate. The median age was 58 years (range 13–82), 75.8% were from Europe and 81.8% were male. Nearly 70% of KS patients develop symptoms within 30 min after administration. Chest pain (63.6%) and allergic reaction (75.8%) were the most common clinical manifestations. Diagnostic evaluation revealed elevated troponin (72.7%), ST-segment elevation (81.2%) and coronary artery stenosis with thrombosis (53.6%). Thirty-two (97.0%) patients recovered completely after discontinuation of amoxicillin and treatments such as steroids and antihistamines.

Conclusion: KS is a rare adverse reaction of amoxicillin. Amoxicillin-induced KS should be considered when chest pain accompanied by allergic symptoms, electrocardiogram changes and or elevated levels of myocardial injury markers. Therapeutic management of KS requires simultaneous treatment of cardiac and allergic symptoms. Epinephrine should be used with caution in patients with suspected KS.

Introduction

Kounis syndrome (KS) is an acute coronary syndrome caused by an allergic reaction, and first reported by Kounis and Zavras in 1991 (ounis and Zavras, 1991). Patients with a history of allergies, hypertension, smoking, diabetes, and hyperlipidemia are more likely to be affected. KS can occur at any age, but the most commonly affected age group is 40–70 years (68%) of male patients (74.3%) (Abdelghany et al., 2017). KS seems to have a geographical distribution and is mostly reported in southern Europe, especially in Greece and Turkey (Kounis, 2016). Three variants of KS have been defined. The Type I variant (coronary spasm) includes patients with normal or near-normal coronary arteries but without predisposing factors for coronary artery disease. Allergic reactions result in coronary spasm, with or without elevation of markers of myocardial injury. The Type II variant include patients with pre-existing atherosclerotic disease, acute allergy causing plaque erosion or rupture, presenting as acute myocardial infarction. The type III variant variant refers to allergic manifestations and stent thrombosis after coronary drug stent implantation (Kounis, 2016).

A variety of reasons have been found to induce KS, including many drugs, diseases, food, environmental exposure or certain other conditions (Kounis, 2016). Among them, antibiotics are the most common cause of KS, accounting for about 27%, mosquito bites account for about 23% (Abdelghany et al., 2017). Amoxicillin is a commonly used beta-lactam antibiotic and is usually associated with possible adverse events such as gastrointestinal, allergic reactions and haematological reactions (Salvo et al., 2007). KS is a rare and serious complication after the administration of amoxicillin. Knowledge of amoxicillin-induced KS is largely based on case reports. The clinical features of KS induced by amoxicillin are still unclear. The purpose of this study is to explore the clinical characteristics of KS induced by amoxicillin, and to provide a basis for the rational use of amoxicillin.

Methods

Search strategy

We searched the literature related to amoxicillin-induced KS by searching Chinese databases (Wanfang Data, China National Knowledge Infrastructure (CNKI), Chinese VIP) and English databases (PubMed/Medline, Embase, Web of Knowledge, OVID, Elsevier, Springer Link and Cochrane Library databases) from 1972 to May 2022. The search combined subject and free words such as amoxicillin, amoxicillin-clavulanate, Kounis syndrome, antibiotics, allergic reactions, β-lactams, thrombosis, myocardial infarction, acute coronary syndrome, coronary spasm, hypersensitivity.

Inclusion and exclusion criteria

Inclusion criteria: case report and case analysis of KS induced by amoxicillin. The clinical data is relatively complete, including the amoxicillin application, clinical manifestations, laboratory examinations, treatment and prognosis etc. Exclusion criteria: duplicate literature, reviews, mechanistic studies, animal studies and articles for which the full text was not available.

Data extraction

Two researchers independently conducted a preliminary screening of the literature according to the inclusion and exclusion criteria, and then the group discussed the included literature. We extract the following information of patients: region, gender, age, medical history, drug combination, amoxicillin application, indication, symptom onset time, clinical manifestations, laboratory examinations, imaging examinations, treatment and prognosis by using self-designed data extraction table.

Statistical analysis

Statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL). Continuous data is represented by median value with ranges, counting data is represented by number of cases and percentage (%).

Results

Basic information

As shown in Figure 1, a total of 456 relevant studies were initially identified. One hundred and fifty-six duplicate studies were excluded. After an initial screening of titles and abstracts, 218 articles were removed. Of the remaining 79 studies, 48 were excluded from the full-text review. A total of 31 studies were included (Alemparte Pardavila et al., 1999; López-Abad et al., 2004; Moreno-Ancillo et al., 2004; Gikas et al., 2005; Del Furia et al., 2007; Tigen et al., 2007; Tavil et al., 2008; Vivas et al., 2008; Biteker et al., 2009; Caglar et al., 2011; Venturini et al., 2011; Viana-Tejedor et al., 2011; Mazarakis et al., 2012; Bezgin et al., 2013; Calf et al., 2013; Ilhan et al., 2013; Kilickesmez et al., 2013; Lombardi et al., 2013; González-de-Olano et al., 2014; Ralapanawa and Kularatne, 2015; Molina Anguita et al., 2016; Salouage et al., 2016; Shimi et al., 2016; Antonelli et al., 2017; Canpolat et al., 2017; Omri et al., 2017; Pradhan et al., 2018; Lopes and Agarwal, 2019; Moloney et al., 2019; Caragnano et al., 2020; Duarte et al., 2020). The basic information of these 33 patients is summarized in Table 1. These patients included 27 males (81.8%) and 6 females with a median age of 58years (range 13–82). These patients include 25 cases (75.8%) in Europe, 3 patients (9.1%) in Africa, 2 patients (6.1%) in Asia, and 2 patients (6.1%)) in the United States, 1 patient (3.0%) in Oceania. Amoxicillin and amoxicillin-clavulanate are primarily used for infection and dental care prophylaxis. There were 16 patients with other diseases, including hypertension in 8 patients (24.2%), dyslipidemia in 6 patients (18.2%), diabetes in 4 patients (12.1%), ischemic heart disease in 3 patients (9.1%). Eight patients (24.2%) had a history of smoking habits (Vivas et al., 2008; Venturini et al., 2011; Mazarakis et al., 2012; Lombardi et al., 2013; Salouage et al., 2016; Pradhan et al., 2018; Caragnano et al., 2020). Four patients (12.1%) had previous history of penicillin-allergy (Antonelli et al., 2017; Omri et al., 2017; Caragnano et al., 2020; Duarte et al., 2020). Five patients (15.2%) were treated with other drugs concurrently.

FIGURE 1

FIGURE 1

Flow chart of the study selection process for reported cases of amoxicillin-induced Kounis syndrome.

TABLE 1

ReferenceAge/GenderDrugDaily dosage (g)Route of administrationTime of symptom onsetSymptomsTroponin I (ng/ml)ECGEchocardiographyCoronarographyKS typeTreatment
5M/62AC0.5oral15 minUnconsciousness, skin vasodilationNAST elevationNAStenosisIIdopamine
6M/56AC0.5oral30 minCP, D, R1.37normalnormalNANAsteroids, antihistamines, NG
7M/32AC0.5oral2 h 15 mindizziness, blurred vision, D, abdominal pain, anaphylaxis45.5ST elevationEF 60%normalIsteroids, E, aspirin, UF, pethidine, NG, reteplase
8F/70AC0.5oralFew minP, warmth, flushing, lips and hands swelling, D, unconscious0.31ST elevationhypokinesisstenosisIIsteroids, antihistamines, aspirin, nitrates
9M/69ACfirst doseIVFew minCP, epigastric discomfortnormalST elevationnormalnormalIsteroids, NG, CCB
10F/40ACfirst doseoral20 minCP, swollen extremities, R, tongue swelling, dysphagia11.65ST elevationEF 50%, hypokinesisStenosisIIsteroids, antihistamines, tirofiban, clopidogrel, metoprolol, ramipril, atorvastatin.
11M/64ACNAoralimmediatelyCP, erythema, N, V4.48aST elevationnormalthrombosisIING, antihistamines
12M/48AC2oral3dCP, R, S3.7ST elevationEF 40%, hypokinesisstenosisIIIsteroids, antihistamines, simvastatin, aspirin, atenolol, nitrates, clopidogrel
13M/64AC1oral5 minchest discomfort, unconsciousness, R, S2.1ST elevationNAstenosisIIsteroids, antihistamines, aspirin, clopidogrel, UF
14M/71ACa tabletoralwithin minV, U, P, dizziness, hypotension0.266ST depressionNANANAsteroids, antihistamines, E
15F/61AC0.25oral10minV, despair, diarrhea, dizziness, fainting0.245negative T-wavenormalNAIsteroids, antihistamines
16M/53ACNAoralFew minCP, U, P, ventricular, fibrillation1,272ST elevationNANANAsteroids, antihistamines
17M/60AC1oralimmediatelyCP, altered mental status, dizziness, P, warmth, flushing, D, U0.0047ST elevationEF 30%, hypokinesisStenosis, occlusionIIsteroids, antihistamines, UF, clopidogrel, streptokinase
18M/62AC0.5oralimmediatelygeneral asthenia, face erythema0.064ST elevationEF 55%stenosisIIadrenaline, mechanical ventilation
19M/22ACsingleoral1 hCP, chest tightness0.550ST elevationnormalnormalIaspirin, UF
20M/64AC1oralAfter 5 tabletsCP, weakness, S0.14repolarization abnormalitiesNAsubocclusionIisosorbide dinitrate, aspirin, LMWH
20M/57ACA0.875oral15 minCP, N, R, P3.78ST elevationEF 55%, hypokinesisnormalIsteroids, antihistamines
20M/58ACA0.875oralFew minCP, R, DnormalST elevationNAnormalIsteroids, antihistamines
21F/58ACANAoral1 hCP, flushing, P, warmth, facial oedema, U, dizziness0.51Pardee wavesNAthrombosisIIIsteroids, morphine, E, UF
22F/56ACA2oralImmediatelychest discomfort, N, V, S, erythema, U7.9ST depressionEF 60%normalIsteroids, antihistamines, ephedrine, aspirin, clopidogrel
23M/54ACA1oral30 minCP, P, NNAST elevationEF 30%, hypokinesisvasospasmIaspirin, clopidogrel, UF, nitrate
24M/53ACANAoralNACP, D, S, N, dizziness, cyanosed lips, UNAST-elevationNAstenosisIIsteroids, adrenaline, aspirin, fentanyl, UF, ticagrelor
25F/73ACANAIV1 minR, altered state of consciousness2046ST elevationNAstenosisIIsteroids, antihistamines, advanced life support, mechanical ventilation
26M/74ACA1.2IV20 minanaphylactic shock, R, P, palpitations, chest tightness, S2.2ST elevationhypokinesisNANAsteroids, antihistamines, adrenalin, aspirin, clopidogrel, atovastatin
27M/43ACANAoralNACP, P, erythemaNAST elevationNAnormalIsteroids, antihistamines, oxygen
28M/61ACA1oral10 minCP, R0.288aST elevationNAnormalIIantihistamine
29M/13ACA0.5oral30 minCP, R13ST elevationhypokinesisnormalIsteroids, antihistamines
30M/31ACANAoral1 hangina pectorisST elevationnormalstenosisNAthrombolytic therapy (tPA)
31M/29ACA1oralNACP, D29ST elevationnormalnormalIsteroids, antihistamines, morphine
32M/16ACA1oralNAischemic painNAST elevationnormalnormalINA
33M/82ACANAIVImmediatelyabdominal pain, D, erythematous, RNAST elevationNAnormalIsteroids, antihistamines, aspirin, UF
34M/58ACA0.875oral30 minCP, D, weakness, S, hypotensionnormalST elevationNAnormalIE
35M/25ACA1oral20 minCP, R2.40aST elevationhypokinesisnormalING, anti-ischemic and anti-platelet drugs

Summary of clinical information of 33 patients with amoxicillin-induced Kounis syndrome.

Abbreviation: AC, amoxicillin; ACA, amoxicillin and clavulanic acid; IV, intravenous; CP, chest pain; V, vomiting, N, nausea; P, pruritus; S, sweating; D, dyspnea; R, rash, U, urticaria; Electrocardiogram; LMWH, low molecular weight heparin; UF, unfractionated heparin; tPA, tissue plasminogen activator; CCB, calcium channel blockers; NG, nitroglycerine; ECG, E, epinephrine. Na, Not applicable.

a

Represents the value of Troponin T.

Administration of amoxicillin

In these patients, 16 patients (48.5%) received amoxicillin and 17 patients (51.5%) received amoxicillin-clavulanate (Table 2). The daily dose of amoxicillin ranged from 0.25 g to 2 g, and the dose range of amoxicillin-clavulanate ranged from 0.5 g to 2 g. The route of administration was oral in 29 patients (87.9%) and intravenous in 4 patients (12.9%). KS had a wide range of onset times, from immediately after taking the medicines to 3 days. Symptoms occurred immediately after taking the medicines in 5 patients (15.2%), within half an hour in 18 patients (54.5%), 1 h in 3 patients (3.0%), 2 h 15 min in 1 patient (3.0%), after taking the 5th tablet in 1 patient (3.0%), and 3 days in 1 patient (3.0%). Two patients (6.1%) developed similar symptoms after taking amoxicillin in their previous medical history (Del Furia et al., 2007; Tavil et al., 2008). One patient (3.0%) took amoxycillin in the past without any related symptoms (Gikas et al., 2005). Symptoms reappeared in 1 patient (3.0%) who received amoxicillin again (Moreno-Ancillo et al., 2004).

TABLE 2

ParameterClinical featuresValue
Sexmales27 (81.8%)
females6 (18.2%)
Ageyears58 (13-82)b
RaceEurope25 (75.8%)
Africa3 (9.1%)
Asia2 (6.1%)
USA2 (6.1%)
Oceania1 (3.0%)
Drugamoxicillin16 (48.5%)
amoxicillin-clavulanate17 (51.5%)
Route of administrationoral29 (87.9%)
intravenous injection4 (12.9%)
Symptom onset time (29)aimmediately5 (15.2%)
within 30 min18 (54.5%)
1 h3 (9.1%)
2 h 15 min1 (3.0%)
3 days1 (3.0%)
5th tablet1 (3.0%)
Indicationupper respiratory tract infection9 (27.3%)
dental infection5 (15.2%)
dental care prophylaxis3 (9.1%)
pulmonary infection2 (6.1%)
flu2 (6.1%)
urinary tract infection2 (6.1%)
trauma1 (3.0%)
systemic inflammatory response syndrome1 (3.0%)
na8 (24.2%)
Medical history (16)ahypertension8 (24.2%)
dyslipidemia6 (18.2%)
diabetes4 (12.1%)
ischemic heart disease3 (9.1%)
thyroid disease2 (6.1%)
cerebrovascular disease2 (6.1%
asthma2 (6.1%)
vesical neoplasy1 (3.0%)
volvulus1 (3.0%)
epilepsy1 (3.0%)
Risk factorspenicillin-allergy4 (12.1%)
non-steroidal anti-inflammatory drugs food allergy1 (3.0%)
smoking1 (3.0%)
8 (24.2%)
combination therapynebivolol/hydrochlorothiazide, doxazosin, insulin, clopidogrel, captopril, furosemide, metformin, aspirin, statins, tapazole5 (15.2%)

Basic information of 33 patients with amoxicillin-induced Kounis syndrome.

a

Represents the number of patients out of 33 on which information regarding this particular parameter was provided.

b

Median (minimum-maximum).

Abbreviations: na, not applicable.

Clinical manifestations

The clinical symptoms of 33 KS patients are summarized in Table 3. The main clinical manifestations of these patients included chest pain in 21 patients (63.6%), allergic reactions (rash, pruritus, erythema) in 25 patients (75.8%), neurological adverse reactions (alteration of consciousness, dizziness) in 10 patients (30.3%), and gastrointestinal adverse reactions (nausea, vomiting, abdominal pain) in 10 patients (30.3%), dyspnea in 6 patients (18.2%), swelling (lips, hands, tongue, face) in 2 patients (6.1%). Thirteen patients had hypotension at the onset of symptoms (Alemparte Pardavila et al., 1999; López-Abad et al., 2004; Gikas et al., 2005; Vivas et al., 2008; Mazarakis et al., 2012; Kilickesmez et al., 2013; Lombardi et al., 2013; González-de-Olano et al., 2014; Ralapanawa and Kularatne, 2015; Salouage et al., 2016; Shimi et al., 2016; Duarte et al., 2020). Cardiac arrest occurred in 4 patients (12.1%) (Calf et al., 2013; Canpolat et al., 2017; Caragnano et al., 2020; Duarte et al., 2020).

TABLE 3

ParameterClinical featuresValue
Symtomschest pain21 (63.6%)
allergic reactions (rash, pruritus, erythema)25 (75.8%)
neurological adverse reactions (alteration of consciousness, dizziness)10 (30.3%)
gastrointestinal adverse reactions (nausea, vomiting, abdominal pain)10 (30.3%)
hypotension13 (36.3%)
dyspnea6 (18.2%)
cardiac arrest4 (12.1%)
chest discomfort2 (6.1%)
swelling (lips, hands, tongue, face)2 (6.1%)
chest tightness1 (3.0%)
ElectrocardiogramST elevation27 (81.2%)
depression2 (6.1%)
pardee waves1 (3.0%)
left ventricular repolarization abnormalities1 (3.0%)
negative T-wave1 (3.0%)
normal1 (3.0%)
Echocardiography (20) anormal13 (65.0%)
hypokinesis9 (45.0%)
reduced ejection fraction3 (15.0%)
Coronary angiography (28) anormal14 (50.0%)
stenosis12 (42.9%)
thrombosis2 (7.1%)
left coronary artery8 (28.6%)
right coronary artery4 (14.3%)
Laboratory examination (27)atroponin T3 (11.1%)
elevated3 (11.1%)
troponin I24 (88.9%)
normal3 (11.1%)
elevated21 (77.8%)
2.2 (0.064, 2046) b
creatine kinase15 (45.5%)
normal5 (15.2%)
elevated10 (30.3%)
creatine kinase-myocardial band9 (27.3%)
elevated9 (27.3%)
serum tryptase5 (15.2%)
elevated5 (15.2%)
skin prick tests10 (30.3%)
positive10 (30.3%)

Clinical symptoms, imaging and laboratory tests of 33 patients with amoxicillin-induced Kounis syndrome.

a

Represents the number of patients out of 33 on which information regarding this particular parameter was provided.

b

Median (minimum-maximum).

Laboratory examination

The laboratory tests of 33 KS patients are summarized in Table 2. Laboratory exams of troponin and tryptase performed after the beginning of the episode in some patients. Of the 27 recorded cases, 3 patients (11.1%) had elevated troponin T, 3 patients (11.1%) had normal troponin I, and 21 patients (77.8%) had elevated troponin I, with a median of 2.2 ng/ml (range 0.064–2046). Creatine kinase (CK) was reported in 15 patients(45.5%), with elevations in 10 patients (30.3%) (Alemparte Pardavila et al., 1999; Moreno-Ancillo et al., 2004; Gikas et al., 2005; Tigen et al., 2007; Caglar et al., 2011; Viana-Tejedor et al., 2011; Bezgin et al., 2013; Antonelli et al., 2017; Pradhan et al., 2018; Duarte et al., 2020). Nine patients (27.3%) reported elevated creatine kinase-myocardial band (CK-MB) (Moreno-Ancillo et al., 2004; Gikas et al., 2005; Tigen et al., 2007; Tavil et al., 2008; Biteker et al., 2009; Venturini et al., 2011; Bezgin et al., 2013; Kilickesmez et al., 2013; Omri et al., 2017). The serum tryptase levels were significantly elevated in 5 patients (15.2%) undergoing examination (Biteker et al., 2009; González-de-Olano et al., 2014; Molina Anguita et al., 2016; Lopes and Agarwal, 2019; Duarte et al., 2020). The results were positive in 10 patients (30.3%) undergoing skin prick tests (Alemparte Pardavila et al., 1999; López-Abad et al., 2004; Moreno-Ancillo et al., 2004; Gikas et al., 2005; Del Furia et al., 2007; Vivas et al., 2008; Bezgin et al., 2013; Kilickesmez et al., 2013; González-de-Olano et al., 2014; Molina Anguita et al., 2016).

Imaging examination

The imaging examinations of 33 KS patients are summarized in Table 2. Electrocardiogram (ECG) examination mainly showed ST segment elevation in 27 patients (81.2%). Very few patients showed pardee waves (3.0%), depression (6.1%), left ventricular repolarization abnormalities (3.0%) and negative T-wave (3.0%) on ECG. Only 1 patient had normal ECG (3.0%). Echocardiography in 20 patients (60.6%) at the onset of KS showed normal in 13 patients (65.0%), hypokinesis in 9 patients (45.0%), and reduced ejection fraction in 3 patients (15.0%) (Venturini et al., 2011; Canpolat et al., 2017; Caragnano et al., 2020). Coronary angiography in 28 patients showed normal in 14 patients (50.0%), stenosis in 12 patients (42.9%), and thrombosis in 2 patients (7.1%) (Viana-Tejedor et al., 2011; Salouage et al., 2016). The left coronary artery (LCA) was affected in 8 patients (28.6%), (Del Furia et al., 2007; Caglar et al., 2011; Viana-Tejedor et al., 2011; Mazarakis et al., 2012; Lombardi et al., 2013; Salouage et al., 2016; Omri et al., 2017; Moloney et al., 2019), and the right coronary artery (RCA) was affected in 4 patients (14.3%) (Tigen et al., 2007; Viana-Tejedor et al., 2011; Mazarakis et al., 2012; Canpolat et al., 2017).

Treatment and prognosis

The treatment and prognosis of the 33 KS patients are summarized in Table 4. All patients immediately withdrew amoxicillin and amoxicillin-clavulanate after the onset of symptoms (Table 2). The remaining treatment options included steroids in 22 patients (66.7%), antihistamines in 20 patients (66.0%), epinephrine in 6 patients (18.2%), nitrate in 8 patients (24.2%), anti-platelet drugs in 14 patients (42.4%), anticoagulant drugs in 10 patients (30.3%), thrombolytic therapy in 1 patient (3.0%). Revascularization was performed in 9 patients (27.3%), including percutaneous coronary intervention (PCI) in 8 patients (24.2%), coronary artery bypass surgery (CABS) in 1 patient (3.0%) (Alemparte Pardavila et al., 1999; Del Furia et al., 2007; Caglar et al., 2011; Venturini et al., 2011; Mazarakis et al., 2012; Lombardi et al., 2013; Antonelli et al., 2017; Omri et al., 2017; Moloney et al., 2019). Thirty-two patients (97.0%) recovered completely, and only one patient (3.0%) died (Omri et al., 2017).

TABLE 4

ParameterValue
Treatmentdiscounted33 (100%)
steroids22 (66.7%)
antihistamines20 (66.0%)
epinephrine6 (18.2%)
nitrate8 (24.2%)
anti-platelet drugs14 (42.4%)
anticoagulant drugs10 (30.3%)
thrombolytic therapy1 (3.0%)
cardiac resuscitation1 (3.0%)
percutaneous coronary intervention8 (24.2%)
coronary artery bypass surgery1 (3.0%)
Outcomerecovered32 (97.0%)
died1 (3.0%)
Kounis syndrome variantsI16 (48.5%)
II10 (30.3%)
III2 (6.1%)
na5 (15.2%)

Treatment and prognosis of 33 patients with amoxicillin-induced Kounis syndrome.

Abbreviations: na, not applicable.

Types of Kounis syndrome

Sixteen patients (48.5%) belonged to type I KS variant, 10 patients (30.3%) belonged to type II KS variant, 2 patients (6.1%) belonged to type III KS variant. The KS variant could not be identified in the remaining 5 patients (15.2%).

Discussion

KS is an allergic acute coronary syndrome that can occur at any age, but the most commonly affected age group is 40–70 years (68%) of male patients (74.3%). Patients with a history of allergies, hypertension, smoking, diabetes, and hyperlipidemia are more likely to be affected (Abdelghany et al., 2017). Among the 33 reported cases of KS induced by amoxicillin, the majority were type I variant, the patients were mainly middle-aged men from Europe. Approximately 70% of cases occur within 30 min after administration. The diagnosis of KS mainly relies on clinical symptoms and signs as well as laboratory tests, electrocardiogram, echocardiography and coronary angiography. In addition to the typical symptoms of chest pain, allergic reactions will appear, including rash, hives. Cardiac troponin I or T and myocardial enzymes (CK, CK-MB) are important markers of myocardial injury. ECG usually showed ischemia-related ST-segment changes, of which ST-segment elevation was the most common manifestation. Coronary angiography may show spasm or stenosis of coronary vessels. The study showed that LCA was the culprit in approximately one-third of patients with coronary vasospasm or stenosis.

It is currently believed that the occurrence of KS is caused by allergic reactions in people with allergies after exposure to specific antigens. The main inflammatory cells that are involved in the development of KS are mast cells that interact with macrophages and T-lymphocytes (Fassio et al., 2016). Infiltration of activated mast cells into plaque erosion or rupture areas is a common pathway between allergic and non-allergic coronary events (Kovanen et al., 1995). These activated cells release inflammatory mediators, including histamine, neutral proteases, arachidonic acid products, platelet activating factor and heparin, etc., leading to peripheral vasodilatation, hypotension, coronary spasm, and coronary atherosclerosis erosion, rupture of plaque-like plaques or thrombosis in coronary stents (Abdelghany et al., 2017).

At present, the guideline for the treatment of KS have not been established, and the treatment recommendations are mainly derived from the experience summary of case reports. The treatment of KS should consider two aspects of acute coronary syndrome (ACS) and allergic reaction. Patients with ACS should be treated according to the ACS guidelines. Anti-allergic treatment often has a better effect in patients with type I KS variant, while patients with type II variant and III KS variant need to treat acute coronary syndromes while being anti-allergic (Abdelghany et al., 2017). Corticosteroids and H1 and H2 antihistamines can all reduce or eliminate allergy symptoms. The administration of vasodilators such as calcium channel blockers and nitrates can abolish hypersensitivity induced vasospasm. Epinephrine should be used with caution in KS, because it can aggravate myocardial ischemia, prolong the QTc interval and induce coronary vasospasm and arrhythmia (Fassio et al., 2016). Stabilizing mast cells and preventing the release of inflammatory mediators may be a new therapeutic strategy for KS. Drugs and natural molecules that stabilize mast cells include mediator antagonists, mediator biosynthesis inhibitors, leukotriene antagonists, mediator receptor blockers such as sodium nedocromil, sodium cromoglycate, ketotifen, lodoxamide, humanized IgG1 monoclonal antibodies and others which interfere with mast cell stabilization (Cevik et al., 2010).

KS has a good prognosis and can fully recover with appropriate treatment in most patients. Our research showed that amoxicillin-induced KS may have serious complications, such as cardiac arrest in 12.1% of patients and death in 3% of patients.

Conclusion

In conclusion, KS is a rare adverse reaction of amoxicillin. Amoxicillin-induced KS should be considered when chest pain accompanied by allergic symptoms, ECG changes and or elevated levels of myocardial injury markers.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

CW and SZ conceived of the presented idea. CW, YZ, WF, ZL and SZ wrote the manuscript. All authors discussed the results and contributed to the final manuscript.

Funding

This study was funded by the Hunan Provincial Natural Science Foundation (No.2021JJ80083).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    AbdelghanyM.SubediR.ShahS.KozmanH. (2017). Kounis syndrome: A review article on epidemiology, diagnostic findings, management and complications of allergic acute coronary syndrome. Int. J. Cardiol.232, 14. 10.1016/j.ijcard.2017.01.124

  • 2

    Alemparte PardavilaE.Castro BeirasA.Vazquez GoNzalezN.Lopez RicoM. R. (1999). Acute myocardial infarction after anaphylactic reaction to amoxicillin. Rev. Esp. Cardiol.52 (8), 622624. 10.1016/s0300-8932(99)74979-1

  • 3

    AntonelliD.RoznerE.TurgemanY. (2017). Kounis syndrome: Acute ST segment elevation myocardial infarction following allergic reaction to amoxicillin. Isr. Med. Assoc. J.19 (1), 5960.

  • 4

    BezginT.GeçmenÇ.ÖzkanB.AliciG.KalkanM. E.KarginR.et al (2013). Kounis syndrome secondary to simultaneous oral amoxicillin and parenteral ampicillin use in a young man. Cardiovasc. J. Afr.24 (2), e10e12. 10.5830/CVJA-2012-077

  • 5

    BitekerM.DuranN. E.BitekerF. S.ErtürkE.AykanA. C.CivanH. A.et al (2009). Kounis syndrome secondary to amoxicillin/clavulanic acid use in a child. Int. J. Cardiol.136 (1), e3e5. 10.1016/j.ijcard.2008.04.064

  • 6

    CaglarF. N.CaglarI. M.CoskunU.UgurlucanM.OkcunB. (2011). Kounis syndrome: Myocardial infarction secondary to an allergic insult--a rare clinical entity. Acta Cardiol.66 (4), 559562. 10.1080/ac.66.4.2126625

  • 7

    CalfA. H.MeijerE.TakensL. H.HobbeltA. H.JanssenW. M. (2013). Cardiorespiratory arrest after administration of an antibiotic. Neth. J. Med.71 (10528), 528532.

  • 8

    CanpolatU.KoçyiğitD.AytemirK. (2017). Interesting presentation of Kounis syndrome secondary to amoxicillin/ clavulanate use: Coronary vasospasm and simultaneous appropriate implantable defibrillator shock. Turk Kardiyol. Dern. Ars.45 (5), 466469. 10.5543/tkda.2017.38845

  • 9

    CaragnanoV.DistasoS.ScicchitanoP.ChieppaD. R. R.LiotinoM.ScialpiA.et al (2020). Cardiac arrest in type II Kounis syndrome after oral intake of amoxicilline. Am. J. Cardiovasc. Dis.10 (3), 195200.

  • 10

    CevikC.NugentK.ShomeG. P.KounisN. G. (2010). Treatment of kounis syndrome. Int. J. Cardiol.143, 223226. 10.1016/j.ijcard.2010.02.040

  • 11

    Del FuriaF.QuercetoL.TestiS.SantoroG. M. (2007). Acute ST-segment elevation myocardial infarction complicating amoxycillin-induced anaphylaxis: A case report. Int. J. Cardiol.117 (1), e37e39. 10.1016/j.ijcard.2006.11.097

  • 12

    DuarteP.CostaJ.SerenaC.AlmeidaC.GouveiaS.LourençoC.et al (2020). Kounis syndrome. Apropos of a clinical case. Rev. Bras. Ter. Intensiva32 (1), 149152. 10.5935/0103-507x.20200021

  • 13

    FassioF.LosappioL.Antolin-AmerigoD.PeveriS.PalaG.PreziosiD.et al (2016). Kounis syndrome: A concise review with focus on management. Eur. J. Intern. Med.30, 710. 10.1016/j.ejim.2015.12.004

  • 14

    GikasA.LazarosG.Kontou-FiliK. (2005). Acute ST-segment elevation myocardial infarction after amoxycillin-induced anaphylactic shock in a young adult with normal coronary arteries: A case report. BMC Cardiovasc. Disord.5 (1), 6. 10.1186/1471-2261-5-6

  • 15

    González-de-OlanoD.Gandolfo-CanoM.Mohedano-VicenteE.González-ManceboE.MatitoA.KounisN. G.et al (2014). Kounis syndrome following the performance of skin test to amoxicillin. Int. J. Cardiol.174 (3), 856857. 10.1016/j.ijcard.2014.04.191

  • 16

    IlhanE.AkbulutT.GürsürerM. (2013). An underdiagnosed syndrome; Kounis syndrome secondary to amoxicillin/clavulanic acid use in a 16 year-old child. Int. J. Cardiol.167 (4), e90e91. 10.1016/j.ijcard.2013.03.158

  • 17

    KilickesmezK. O.AbaciO.EzzatO.CoskunU.KucukogluS. (2013). Acute myocardial infarction after the use of amoxicillin/clavulanic acid: type I kounis syndrome. yeditepemj. (15), 304308. 10.15659/yeditepemj.15.10.207

  • 18

    KounisN. G. (2016). Kounis syndrome: An update on epidemiology, pathogenesis, diagnosis and therapeutic management. Clin. Chem. Lab. Med.54 (10), 15451559. 10.1515/cclm-2016-0010

  • 19

    KovanenP. T.KaartinenM.PaavonenT. (1995). Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation92, 10841088. 10.1161/01.cir.92.5.1084

  • 20

    LombardiN.PugiA.MagginiV.LentiM. C.MugelliA.CecchiE.et al (2013). Underdiagnosis and pharmacovigilance. The case of allergic acute coronary syndrome (Kounis syndrome). Int. J. Cardiol.168 (5), 50545055. 10.1016/j.ijcard.2013.07.209

  • 21

    LopesJ. M.AgarwalS. (2019). M012 amoxicillin-clavulanate-induced kounis syndrome. Ann. Allergy, Asthma & Immunol.123 (5), S67. 10.1016/j.anai.2019.08.090

  • 22

    López-AbadR.RodríguezF.García-AbujetaJ. L.Martín-GilD.JerezJ. (2004). Myocardial ischemia due to severe amoxicillin allergy. J. Investig. Allergol. Clin. Immunol.14 (2), 162164. 10.1093/jac/dkm111

  • 23

    MazarakisA.AlmpanisG. C.PapathanasiouP.KounisN. G. (2012). Kounis syndrome uncovers critical left main coronary disease: The question of administering epinephrine. Int. J. Cardiol.157 (3), e43e45. 10.1016/j.ijcard.2011.09.075

  • 24

    Molina AnguitaM.García RodríguezC.Méndez DíazY.Galindo BonillaP. A. (2016). Kounis syndrome: A diagnostic urgency. Semergen42 (7), e133e135. 10.1016/j.semerg.2015.11.007

  • 25

    MoloneyN.PagetS.KeijzersG. (2019). Kounis syndrome: Anaphylaxis causing coronary occlusion. Emerg. Med. Australas.31 (5), 903905. 10.1111/1742-6723.13377

  • 26

    Moreno-AncilloA.Domínguez-NocheC.Gil-AdradosA. C.Cosmes MartnP. M. (2004). Acute coronary syndrome due to amoxicillin allergy. Allergy59 (4), 466467. 10.1046/j.1398-9995.2003.00414.x

  • 27

    OmriM.KraiemH.MejriO.NaijaM.ChebiliN. (2017). Management of kounis syndrome: Two case reports. J. Med. Case Rep.11 (1), 145. 10.1186/s13256-017-1310-7

  • 28

    ounisK. N. G.ZavrasG. M. (1991). Histamine-induced coronary artery spasm: The concept of allergic angina. Br. J. Clin. Pract.45 (2), 121128.

  • 29

    PradhanS.ChristM.TrappeH. J. (2018). Kounis syndrome induced by amoxicillin following vasospastic coronary event in a 22-year-old patient: A case report. Cardiovasc. Diagn. Ther.8 (2), 180185. 10.21037/cdt.2018.03.07

  • 30

    RalapanawaD. M.KularatneS. A. (2015). Kounis syndrome secondary to amoxicillin/clavulanic acid administration: A case report and review of literature. BMC Res. Notes8, 97. 10.1186/s13104-015-1072-5

  • 31

    SalouageI.El AidliS.KastalliS.DaghfousR.LakhalM. (2016). Fatal kounis syndrome with stent thrombosis secondary to amoxicillin/clavulanic acid use: A case report and literature review. Therapie71 (6), 535539. 10.1016/j.therap.2016.06.004

  • 32

    SalvoF.PolimeniG.MorettiU.ConfortiA.LeoneR.LeoniO.et al (2007). Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: Data from spontaneous reporting in Italy. J. Antimicrob. Chemother.60 (1), 121126. 10.1093/jac/dkm111

  • 33

    ShimiA.TouzaniS.DerkaouiA.KhatoufM.DerkAouiA. (2016). Kounis syndrome associated with amoxicillin/clavulanic acid. Saudi J. Anaesth.10 (4), 444445. 10.4103/1658-354X.177329

  • 34

    TavilY.TurfanM.TürkoğluS.AbaciA. (2008). Kounis syndrome secondary to amoxicillin/clavulanic acid use. Int. J. Cardiol.124 (1), e4e7. 10.1016/j.ijcard.2006.11.165

  • 35

    TigenK.CevikC.BasaranY. (2007). Acute myocardial infarction following amoxicillin allergy: Coronary angiography and intravascular ultrasound findings. Acta Cardiol.62 (5), 525528. 10.2143/AC.62.5.2023420

  • 36

    VenturiniE.MagniL.KounisN. G. (2011). Amoxicillin-induced Kounis syndrome manifesting as late stent thrombosis. Int. J. Cardiol.151 (1), e26e28. 10.1016/j.ijcard.2010.04.069

  • 37

    Viana-TejedorA.EspinosaM. Á.CuestaJ.NúñezA.BuenoH.Fernández-AvilésF.et al (2011). Kounis syndrome secondary to amoxicillin use in an asthmatic patient. Int. J. Cardiol.150 (3), e113e115. 10.1016/j.ijcard.2010.02.066

  • 38

    VivasD.RubiraJ. C.OrtizA. F.MacayaC. (2008). Coronary spasm and hypersensitivity to amoxicillin: Kounis or not Kounis syndrome?Int. J. Cardiol.128 (2), 279281. 10.1016/j.ijcard.2007.06.029

Summary

Keywords

Kounis syndrome, amoxicilline, coronary spasm, acute coronary syndrome, hypersensitivity

Citation

Wang C, Zhou Y, Fang W, Li Z and Zhao S (2022) Clinical features, diagnosis and management of amoxicillin-induced Kounis syndrome. Front. Pharmacol. 13:998239. doi: 10.3389/fphar.2022.998239

Received

19 July 2022

Accepted

18 October 2022

Published

31 October 2022

Volume

13 - 2022

Edited by

Patricia Moriel, State University of Campinas, Brazil

Reviewed by

Mihaela Popescu, Carol Davila University of Medicine and Pharmacy, Romania

Godfrey Mutashambara Rwegerera, Sir Ketumile Masire Teaching Hospital, Botswana

Updates

Copyright

*Correspondence: Shaoli Zhao,

This article was submitted to Drugs Outcomes Research and Policies, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics